Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI monotherapy or combination therapy with an alpha-blocker (AB) compared to late initiation of 5ARI therapy in patients receiving combination therapy. The Henry Ford Health System databases will be utilized for this study (2000-2008).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Dutasteride; Finasteride

Criteria

Inclusion Criteria:

• Males

• aged 50 years or older

• medical claim of EP

• prescription claim(s) for either a 5ARI or both 5ARI and AB (provided both are within 180 days of index date)

• continuously eligible for 3 months prior to and at least 5 months after their index prescription date.

Exclusion Criteria:

• Patients with prostate or bladder cancer

• any prostate-related surgical procedure within 5 months of index date

• prescription claim for finasteride indicative of male pattern baldness; AB monotherapy only; initiation of 5ARI occurring more than 180 days after initiation of AB